JUN and esophageal cancer: Collectively, these findings provide evidence supporting the idea that the anticancer efficacy of HOI-02 is mediated in vivo by generation of ROS resulting in increased cleavage of caspase 3, induction of AP-1 and enhanced p21 signaling, all of which contribute to the inhibition of esophageal cancer cell growth.